September 10, 2024 11:55 AM EDT
R&D
Pharma

Lil­ly's week­ly in­sulin hits pri­ma­ry end­points in two more late-stage di­a­betes stud­ies

Katherine Lewin

News Reporter

Eli Lil­ly re­leased two more sets of da­ta for its once-week­ly in­sulin ef­si­to­ra a week af­ter tout­ing da­ta from an­oth­er two tri­als in its late …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

A service from the Financial Times